azacitidine has been researched along with Autoimmune Diseases of the Nervous System in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ho, CJ; Li, SC; Lin, CH; Lin, MH; Lin, PH; Lin, Y; Lu, YT; Tsai, KW; Tsai, MH | 1 |
| Helleday, T; Henter, JI; Herold, N; Kutzner, J; Myrberg, IH; Olsen, TK; Paulin, CBJ; Rudd, SG; Sanjiv, K; Schaller, T | 1 |
2 other study(ies) available for azacitidine and Autoimmune Diseases of the Nervous System
| Article | Year |
|---|---|
S100A6 participates in initiation of autoimmune encephalitis and is under epigenetic control.
Topics: Autoantibodies; Autoimmune Diseases of the Nervous System; Azacitidine; Cell Cycle Proteins; Epigenesis, Genetic; Humans; S100 Calcium Binding Protein A6; S100 Proteins | 2023 |
With me or against me: Tumor suppressor and drug resistance activities of SAMHD1.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Autoimmune Diseases of the Nervous System; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cytarabine; Decitabine; Drug Resistance; Humans; Leukemia, Myeloid; Monomeric GTP-Binding Proteins; Mutation; Nervous System Malformations; SAM Domain and HD Domain-Containing Protein 1; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2017 |